Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib

Journal of Clinical Oncology

Volumn 28, Issue 19, 2010, Pages

  Sideras, Kostandinos ^a,b,c   Menefee, Michael E ^a,b,c   Burton, Jill K ^a,b,c   Erlichman, Charles ^a,b,c   Bible, Keith C ^a,b,c   Ivy, S Percy ^d  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PAZOPANIB; TUMOR MARKER; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AFRICAN AMERICAN; ANOREXIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; ENZYME INHIBITION; FEMALE; HAIR DISCOLORATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPIGMENTATION; LEUKOPENIA; NAUSEA; ONCOCYTOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HAIR; PATHOLOGY; SKIN; THYROID TUMOR;

ADENOMA, OXYPHILIC; ADULT; AFRICAN AMERICANS; FEMALE; HAIR; HUMANS; HYPOPIGMENTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SKIN; SULFONAMIDES; THYROID NEOPLASMS;

EID: 77955491468     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.4432     Document Type: Article

References (11)

1. Hartmann JT, Kanz L: Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol 144:1525-1526, 2008
2. Moss KG, Toner GC, Cherrington JM, et al: Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307:476-480, 2003 (Pubitemid 37310659)
3. Sun A, Akin RS, Cobos E, et al: Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol 8:395-398, 2009
4. Brazzelli V, Roveda E, Prestinari F, et al: Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: A noninvasive colorimetric assessment. Pediatr Dermatol 23:175-178, 2006
5. Tsao AS, Kantarjian H, Cortes J, et al: Imatinib mesylate causes hypopigmentation in the skin. Cancer 98:2483-2487, 2003 (Pubitemid 37466664)
6. Halaban R, Moellmann G: White mutants in mice shedding light on humans. J Invest Dermatol 100:S176-S185, 1993 (suppl 2)
7. Giebel LB, Spritz RA: Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci U S A 88:8696-8699, 1991 (Pubitemid 21915424)
8. Richards KA, Fukai K, Oiso N, et al: A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol 4:288-292, 2001 (Pubitemid 32175105)
9. Spritz RA, Ho L, Strunk KM: Inhibition of proliferation of human melanocytes by a KIT antisense oligodeoxynucleotide: Implications for human piebaldism and mouse dominant white spotting (W). J Invest Dermatol 103:148-150, 1994 (Pubitemid 24234597)
10. Lázár-Molnár E, Hegyesi H, Tóth S, et al: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12:547-554, 2000 (Pubitemid 30453481)
11. Hasan S, Dinh K, Lombardo F, et al: Hypopigmentation in an African patient treated with imatinib mesylate: A case report. J Natl Med Assoc 95:722-724, 2003 (Pubitemid 37099524)